This so-called fitness hack has taken over gyms, apps, and morning routines everywhere, promising faster weight loss and ...
OneSource Specialty Pharma has raised its FY28 revenue forecast from $400 million to over $500 million, driven by strong ...
The potential disadvantages of drugs increasingly used by patients to achieve greater weight loss are often not highlighted ...
The vagus nerve is the longest nerve in our body. Running between the base of the brain down to the lower torso, it carries ...
OneSource Specialty Pharma has raised its FY28 revenue forecast from $400 million to over $500 million, driven by strong demand in its drug-device and biologics sectors.
ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.
Managing obesity with both drugs and lifestyle changes ‘enables clinicians to treat patients holistically, long-term, and in ...
By enhancing metabolism and oxygen consumption, the device can help burn more calories during and after each session, aiding ...
First-of-its-kind AI-powered chronic care management platform moves clinically proven tools outside the doctor's office ...
Investors are currently playing a waiting game with Aim-traded Crystal Amber (CRS: 151p), a UK small-cap fund that has ...
Health company Herbalife has participated in all eight editions of the CIIE, offering weight management products such as ...
Wegovy’s key competitor is Eli Lilly’s GLP-1 drug Mounjaro (tirzepatide), which became India’s top-selling medicine in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback